Autoimmune polyendocrine syndrome type 3, characterized by autoimmune thyroid disease, type 1 diabetes mellitus, and isolated ACTH deficiency, developed during adjuvant nivolumab treatment.

Authors :: Takata M
Nomura M
Yamamura K
Muto M
Komori T
Otsuka A
Kabashima K
Source :: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2022 Aug; Vol. 18 (4), pp. 481-482. Date of Electronic Publication: 2021 Apr 18.
Publication Year :: 2022
Abstract: Autoimmune polyendocrine syndrome (APS) is one of the life-threatening immune-related adverse events (irAEs). We firstly report a case of APS induced by adjuvant nivolumab therapy. Clinicians should be aware of the potential risks of developing severe irAEs when applying adjuvant immunotherapy.<br /> (© 2021 John Wiley & Sons Australia, Ltd.)

Subjects :: Adrenocorticotropic Hormone adverse effects
Adrenocorticotropic Hormone deficiency
Endocrine System Diseases
Genetic Diseases, Inborn
Humans
Hypoglycemia
Nivolumab adverse effects
Diabetes Mellitus, Type 1 chemically induced
Diabetes Mellitus, Type 1 drug therapy
Polyendocrinopathies, Autoimmune chemically induced
Thyroid Diseases chemically induced

Full Text Access

Tools